Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TriPath/Digene

This article was originally published in The Gray Sheet

Executive Summary

TriPath will resubmit its withdrawn PMA supplement application to FDA "at the earliest possible date" for use of SurePath liquid-based Pap test specimen-collection medium samples with Digene's Hybrid Capture 2 (HC2) high-risk human papillomavirus (HPV) DNA test, the firm says. The withdrawal of the August 2004 application follows discussions with FDA that revealed "additional clinical information and analyses would be required," TriPath explains (1"The Gray Sheet" Aug. 30, 2004, In Brief). A Digene PMA supplement for the combination was rejected by FDA in 2002. TriPath reports it achieved profitability for the first time in 2004, earning $605,000 on sales of $68.5 mil., up 27%...

Related Content

UsernamePublicRestriction

Register

MT021583

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel